GlaxoSmithKline Sotrovimab EUA Treatment Guide

A detailed guide for the use of GlaxoSmithKline's sotrovimab under Emergency Use Authorization (EUA) for treating mild-to-moderate COVID-19 in adults and…


GlaxoSmithKline Sotrovimab EUA Treatment Guide - cover page
Brand
GLAXOSMITHKLINE
Document type
User Manual
Language
English
Pages
30
File format
PDF
File size
5.1 MB
Published
21 October, 2026
Updated
21 October, 2026
MD5 checksum
E1D4FF8445819B122DD29E80E47E55DE

About this manual

This document serves as a comprehensive resource for healthcare providers regarding the administration of sotrovimab, an unapproved monoclonal antibody authorized by the FDA under an Emergency Use Authorization (EUA). It outlines specific patient populations eligible for treatment, mandatory requirements for administration, and important safety information. The guide emphasizes that sotrovimab is not authorized for hospitalized patients or those requiring oxygen therapy due to COVID-19.

What's inside

  • Population for treatment
  • Mandatory requirements for administration
  • Important Safety Information
  • Product availability and ordering
  • Infusion site of care recommendations
  • Coding and reimbursement

Frequently asked questions

Who is authorized to receive sotrovimab treatment?

Sotrovimab is authorized for adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive SARS-CoV-2 viral testing who are at high risk for progression to severe COVID-19.

When should sotrovimab be administered?

Sotrovimab should be administered by intravenous infusion as soon as possible after positive results of direct SARS-CoV-2 viral testing and within 10 days of symptom onset.

Is sotrovimab authorized for hospitalized patients?

No, sotrovimab is not authorized for use in patients who are hospitalized due to COVID-19 or those requiring oxygen therapy.

Download PDF (5.1 MB)

More GLAXOSMITHKLINE Manuals


View all GLAXOSMITHKLINE manuals →